Opendata, web and dolomites

iRhom2 in AD SIGNED

iRhom2 in neuroinflammation and pathogenesis of Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iRhom2 in AD project word cloud

Explore the words cloud of the iRhom2 in AD project. It provides you a very rough idea of what is the project "iRhom2 in AD" about.

validated    tace    triggered    beta    near    avant    tangles    emerged    disease    plasma    assays    sepsis    release    treatment    involve    pro    necrosis    neuron    alzheimer    elderly    dementia    alpha    begins    risk    guide    proteomic    additional    cascade    cross    healthy    converting    worsen    ad    events    rheumatoid    tnf    though    consequently    implicated    irhom2    inflammation    regulating    cure    thereby    oligomers    traffic    accumulation    dramatic    cytokine    syndrome    protein    line    model    mechanism    neurofibrillary    ageing    protected    biochemical    membrane    rhomboid    tumor    cognitive    mice    memory    culminating    underlying    maturation    enzyme    trafficking    unless    inflammatory    garde    form    candidates    arthritis    functional    progression    signalling    mouse    therapies    socio    foreseen    neuroinflammation    diseases    genetic    primary    citizens    macrophages    death    economical    decline    play    regulate    plan    pathology    cell    clients    dependent    array    found   

Project "iRhom2 in AD" data sheet

The following table provides information about the project.

Coordinator
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN 

Organization address
address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675
website: http://www.med.tu.muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.sciencedirect.com/science/article/pii/S0945053X16301329
 Total cost 159˙460 €
 EC max contribution 159˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2017-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) coordinator 159˙460.00

Map

 Project objective

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, a syndrome characterized by loss of memory and cognitive decline. AD has a dramatic socio-economical impact that is foreseen to worsen in the near future unless a cure is found. The pathology is triggered by the accumulation of Aβ oligomers that begins a cascade culminating with the formation of neurofibrillary tangles within the neuron and cell death. Neuroinflammation is emerging to play a key role in this process and it has been associated with the progression of the disease. The rhomboid-like protein iRhom2 has been recently identified as a genetic risk factor for AD, even though the underlying mechanism remains to be characterized. iRhom2 recently emerged as a novel pro-inflammatory protein required to traffic TACE (tumor necrosis factor-α converting enzyme) towards the plasma membrane and guide its maturation, thereby regulating the release of TNFα, a cytokine implicated in several inflammatory diseases. Consequently, iRhom2-/- mice are protected from sepsis and rheumatoid arthritis, which involve TNFα-dependent inflammation. In addition, the concept is emerging that iRhom2 may regulate trafficking of additional clients other than TACE, thus controlling other signalling events in neuroinflammation. The main objective of this proposal is to characterize the role of iRhom2 in neuroinflammation and in the progression of AD. I plan to cross an AD mouse model with iRhom2-/- mice and evaluate role of iRhom2 in the progression of the disease. In addition, I will use avant-garde proteomic approaches to identify novel iRhom2 clients in primary macrophages. Candidates relevant in neuroinflammation and AD will be further validated using an array of biochemical and functional assays. From this research I aim to identify new targets to develop therapies for treatment of AD, in line with the objectives of H2020 Work Programme to promote healthy ageing of the EU citizens.

 Publications

year authors and title journal last update
List of publications.
2016 Simone D. Scilabra, Kazuhiro Yamamoto, Martina Pigoni, Kazuma Sakamoto, Stephan A. Müller, Alkmini Papadopoulou, Stefan F. Lichtenthaler, Linda Troeberg, Hideaki Nagase, Kenji Kadomatsu
Dissecting the interaction between tissue inhibitor of metalloproteinases-3 (TIMP-3) and low density lipoprotein receptor-related protein-1 (LRP-1): Development of a “TRAP” to increase levels of TIMP-3 in the tissue
published pages: , ISSN: 0945-053X, DOI: 10.1016/j.matbio.2016.07.004
Matrix Biology 2019-06-14
2016 Stephan A. Müller, Simone D. Scilabra, Stefan F. Lichtenthaler
Proteomic Substrate Identification for Membrane Proteases in the Brain
published pages: , ISSN: 1662-5099, DOI: 10.3389/fnmol.2016.00096
Frontiers in Molecular Neuroscience 9 2019-06-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IRHOM2 IN AD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IRHOM2 IN AD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

DIGILEAD (2020)

Digital leadership, well-being and performance in organizations

Read More